Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiourea, N-(5-Bromo-2-Pyridinyl)-N'-(2-(2-Chloro-3-Ethoxy-6-Fluorophenyl)Ethyl)- SCHEMBL6906082 | 1.00 | ALDH1A1 (0.52) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL14439884 | 0.90 | ALDH1A1 (0.54) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL6905335 | 0.89 | RAB9A (0.55) | RAB9AMAPTNPC1KMT2ASMN1; SMN2 | |
| SCHEMBL6907153 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL2792582 | 0.86 | ALDH1A1 (0.56) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL29657174 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL6963627 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL14439886 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL6905477 | 0.80 | ALDH1A1 (0.67) | ALDH1A1LTC4SRAB9AMAPTNPC1 | |
| SCHEMBL14439885 | 0.78 | LTC4S (0.61) | ALDH1A1LTC4SRAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565561-B1 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS FOR TREATMENT OF BONE BLOOD CANCERS | PROMONTORY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | claimed |
| CN-118987015-A | Application of antisense oligonucleotide in preparation of medicine for treating breast cancer | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| EP-4460308-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | Lixte Biotechnology, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240317787-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-09-26 | — | — | US | claimed |
| US-20240298520-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-09-05 | — | — | US | claimed |
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-07-25 | — | — | US | claimed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118119386-A | Functionalized carboxylic acids and their use for treating diseases | 埃斯佩尔维塔治疗股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| US-20240009212-A1 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF | PROMONTORY THERAPEUTICS INC. (US) | 2024-01-11 | — | — | US | claimed |
| EP-4281058-A2 | FUNCTIONALIZED LONG-CHAIN CARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | claimed |
| EP-4232044-A1 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF | Promontory Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2023133371-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20230144846-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-11 | — | — | US | claimed |
| CN-115974931-A | Organic electroluminescent material and device | 环球展览公司 | 2023-04-18 | — | — | CN | claimed |
| US-20230111520-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| WO-2022159808-A2 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159811-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| EP-4003314-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | claimed |
| WO-2022087173-A1 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF | PHOSPLATIN THERAPEUTICS INC. (US) | 2022-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | ALDH1A1 180/4885LTC4S 688/4885RAB9A 3842/4885 |
| US-20230144846-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OXER1, OCIAD1, OCIAD2 | ALDH1A1 501/4885LTC4S 398/4885RAB9A 819/4885 |
| US-20240009212-A1 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF | PHGDH, HIF1A, HIF1AN | ALDH1A1 865/4885LTC4S 4125/4885RAB9A 2253/4885 |
| US-20230111520-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | ALDH1A1 288/4885LTC4S 1086/4885RAB9A 4161/4885 |
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | LEF1, EFNA1, EML4 | ALDH1A1 131/4885LTC4S 943/4885RAB9A 2013/4885 |
| US-20240317787-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | EPCAM, ORC3, OCIAD1 | ALDH1A1 130/4885LTC4S 2686/4885RAB9A 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.